Azitra's platform uses a strain of the skin microbiome, S. epidermidis, to modify the skin microbiome and deliver therapeutic protein to the target. The platform is modular and can modify S. epidermidis to secrete an array of therapeutically relevant proteins necessary in the treatment of multiple skin diseases.
In May 2018, Azitra announced that it had secured $2.15 million in convertible debt financing to support advancement of the company's pipeline of dermatology and skin care products. The financing was led by new investor Connecticut Innovations, and existing investor Bios Partners. An additional new investor, KdT Ventures, joined the syndicate. This financing brings the total raised to date to $5.4 million.
Azitra raises a $14,000,000 series A round from Bios Partners, Connecticut Innovations, Godfrey Capital and KdT Ventures.
Azitra secured $2.15m in convertible debt financing
Funding was led by Bios Partners and Connecticut Innovations
Azitra raises a $2,900,000 series A round from Bios Partners.
President and CEO
Founder and CSO
The Microbiome Movement: Commensal Cosmetics Offer a Viable Future
Travis Whitfill, Azitra Inc., Farmington, CT and Yale University School of Medicine, New Haven, CT USA